EGFR — Targeted Therapies, Trials & Pipeline
Epidermal growth factor receptor — activating mutations (exon 19 del, L858R, exon 20 insertions) drive NSCLC; also targeted in colorectal and head & neck cancers.
Epidermal growth factor receptor — activating mutations (exon 19 del, L858R, exon 20 insertions) drive NSCLC; also targeted in colorectal and head & neck cancers.